13 reports of this reaction
6.0% of all VARDENAFIL HYDROCHLORIDE reports
#1 most reported adverse reaction
ENTEROCOLITIS INFECTIOUS is the #1 most commonly reported adverse reaction for VARDENAFIL HYDROCHLORIDE, manufactured by Alembic Pharmaceuticals Inc.. There are 13 FDA adverse event reports linking VARDENAFIL HYDROCHLORIDE to ENTEROCOLITIS INFECTIOUS. This represents approximately 6.0% of all 218 adverse event reports for this drug.
Patients taking VARDENAFIL HYDROCHLORIDE who experience enterocolitis infectious should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ENTEROCOLITIS INFECTIOUS is moderately reported among VARDENAFIL HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to enterocolitis infectious, the following adverse reactions have been reported for VARDENAFIL HYDROCHLORIDE:
ENTEROCOLITIS INFECTIOUS has been reported as an adverse event in 13 FDA reports for VARDENAFIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ENTEROCOLITIS INFECTIOUS accounts for approximately 6.0% of all adverse event reports for VARDENAFIL HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience enterocolitis infectious while taking VARDENAFIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.